Overview

This trial is active, not recruiting.

Condition bipolar disorder
Treatments valacyclovir, placebo
Phase phase 2
Sponsor Johns Hopkins University
Collaborator Stanley Medical Research Institute
Start date March 2007
End date August 2012
Trial size 60 participants
Trial identifier NCT00428298, 06TGF-981

Summary

This is a sixteen-week, randomized, double-blind add-on study of valacyclovir versus placebo in approximately 60 outpatients meeting diagnostic criteria for DSM-IV Bipolar I or II disorder, testing positive for HSV-1 and who have demonstrable cognitive impairment defined as a total score of less than 85 (one standard deviation from the normal range) on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Each patient will be randomized to double-blind treatment with either valacyclovir or placebo for sixteen weeks. All subjects will be maintained on a stable regimen of psychiatric drugs prescribed by their treating psychiatrist. Patients will be evaluated every 2 weeks by the treatment team and mood rating scales will be administered at each visit including the YMRS, PANSS and the MADRS. The RBANS will be administered again at 8 and 16 weeks. Both the treatment team and the patient will remain blinded during the course of the study. Following the active treatment phase, patients will receive treatment as clinically indicated.

Primary Hypothesis:

Valacyclovir will be superior to placebo in reducing cognitive symptoms associated with bipolar disorder in subjects who have been previously infected with Herpes Simplex virus I (HSV-1).

Secondary Hypothesis:

Valacyclovir will be superior to placebo in reducing mood symptoms associated with bipolar disorder in subjects who have been previously infected with HSV-1.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
valacyclovir Valtrex
Subjects take two 500 mg capsules twice daily for 16 weeks.
(Placebo Comparator)
placebo
Subjects take two 500 mg capsules twice daily for 16 weeks.

Primary Outcomes

Measure
The primary outcome measure will be The primary outcome measure will be the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
time frame: 16 weeks

Secondary Outcomes

Measure
The secondary outcome measures will be the Young Mania Rating Scale (YMRS), the Positive and Negative Syndrome Scale (PANSS) and the Montgomery Asberg Depression Rating Scale (MADRS).
time frame: 16 weeks

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Be between the ages of 18-65 - Have a diagnosis of Bipolar I or II disorder (as defined by DSM-IV) - Be in active treatment with an outpatient psychiatrist - Test positive for HSV1 - Demonstrate cognitive impairment on the RBANS as defined by a total score of less than 85 (i.e. greater than one standard deviation below normal). Exclusion Criteria: - Either pregnant or nursing - Have been diagnosed with any serious, unstable illnesses including HIV infection or other immunodeficiency condition, hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and hypertension), endocrinologic, neurologic, immunologic, or hematologic disease. Illnesses that are currently well controlled and being treated are not grounds for exclusion. - Have a history of hypersensitivity or intolerance to valacyclovir or acyclovir - Meet criteria for DSM-IV substance abuse (except nicotine and caffeine) within the past 90 days - Had ECT (Electroconvulsive Therapy) within three months prior to randomization - Judged to be at serious suicidal risk; inability to provide informed consent.

Additional Information

Official title A Double Blind Placebo Controlled Study of Valacyclovir in Cognitive Impairment and Mood Symptoms of Bipolar Disorder
Principal investigator Jennifer L Payne, MD
Description Background Herpes Viral Infections and Mental Illness. Recent studies have suggested that chronic, recurrent infections with the herpes family of viruses may play a role in chronic mental illnesses such as schizophrenia and bipolar disorder. Several studies have indicated that individuals with schizophrenia have evidence of increased exposure to Herpes viruses (Buka et al, 2001; Srikanth et al, 1994; Pelonero et al, 1990; Bartova et al, 1987 ) though this has not been found in all studies (Fux et al, 1992; DeLisi et al, 1986; King et al, 1985). Leweke et al (2004) found that untreated individuals with recent first episode schizophrenia had increased levels of serum and CSF IgG antibodies to CMV and Toxoplasma gondii in comparison to controls without psychiatric illness. Notably, serum IgM levels were not increased indicating that infection had not occurred recently. Treated individuals with schizophrenia had similar antibody levels as controls. Finally, Dickerson et al have recently shown that previous HSV-1 infection is associated with cognitive impairment in bipolar disorder, with a relative risk of 22.2 and that this risk was increased in the presence of the COMT158 Val/Val genotype (Dickerson et al, 2006). It is well known that active replication of herpes viruses may occur after extended periods of latency. It has also been shown active replication of the virus in the central nervous system may be triggered by environmental or psychosocial stressors and cause mood and even psychotic symptoms (Koehler and Guth 1979; Schlitt et al. 1985; Fisher, 1996). Taken together with the evidence of increased exposure to Herpes viruses found in individuals with schizophrenia and bipolar disorder, one hypotheses that remains to be tested is that episodic reactivation of HSV-1 in the brain triggered by environmental stressors could be a pathogenic mechanism contributing to symptomatology in a subset of bipolar disorder and schizophrenic patients. Cognitive Impairment in Bipolar Disorder Cognitive, or neuropsychological, functioning is one of the major domains of symptomatology in major mental illness. While cognitive impairment in schizophrenia has been long established, neuropsychological functioning in bipolar disorder has been less extensively studied. Nevertheless, there is evidence that patients with mood disorders frequently manifest cognitive deficits in attention, executive and memory functions (Hoff et al. 1990; Goldberg et al. 1993; Seidman et al. 2002). While symptomatic bipolar disorder patients have been shown to have widespread cognitive abnormalities, evidence from many studies also supports the hypothesis that there are persistent residual cognitive impairments in patients in the euthymic phase of illness (van Gorp et al. 1998; Thompson et al. 2005). As noted above, Dickerson et al have very recently shown an association between HSV-1 seropositivity and cognitive dysfunction in bipolar disorder (2006). Valacyclovir in Schizophrenia Recent studies have shown that herpes viruses may play an etiologic role in the cognitive impairments that occur in a subset of patients with schizophrenia and bipolar disorder. Dickerson et al. (2003a) found that serum antibodies to HSV1 were an independent predictor of cognitive dysfunction in schizophrenia. Similarly, Dickerson et al. (2004) found that serological evidence of infection with HSV1 was also predictive of cognitive impairment in bipolar disorder. This association was independent of other factors that could affect cognition including manic, depressive and psychotic symptoms, age of onset, education, or medications. A clinical trial using the antiviral medication valacyclovir in schizophrenia was recently conducted (Dickerson et al. 2003b). This study found a significant improvement in psychiatric symptoms in individuals with schizophrenia who were seropositive for cytomegalovirus, another virus in the herpes family. This is the first evidence that an antiviral medication may be helpful in a psychiatric condition. The study will be divided into two phases Screening Phase. Subjects will initially be screened by telephone and, if they meet major inclusion and exclusion criteria, will then be invited for an in-person screening. After a consenting process, subjects will first under go RBANS testing. If they meet criteria for cognitive impairment (total score <85) subjects will then go one to have a rapid HSV1 test administered (result available in 1-7 days at Hopkins) and will undergo a Structured Clinical Interview for DSM-IV (SCID) conducted by a research assistant. Subjects who test positive for HSV-1 and who have a diagnosis of Bipolar I or Bipolar II disorder on the SCID will be invited back to meet with a team psychiatrist to complete the screening, including a psychiatric interview and examination, a medical history and physical examination, vital signs, and baseline laboratory tests including a complete blood count and blood chemistries as well as any other evaluation the treatment team feels is medically indicated. Subjects who are appropriate for the study will be invited to join the Active Phase of the study. Active Phase A second consenting process will be conducted for entrance into the active phase of the trial. Subjects will enter this phase within 14 days of the RBANS testing of the screening visit. During this phase the patients will be randomly assigned to receive either valacyclovir or placebo in addition to their standard psychiatric medications. The patients will receive capsules containing valacyclovir or placebo and will be blinded during the course of the study. Valacyclovir will be started at a initial dose of 1000mg twice daily. At the baseline visit, mood rating scales including the YMRS, MADRS, and PANSS will be administered. Please see the Study Schematic (end of Form A) for all scales, history forms, and questionnaires that will be administered during screening and throughout the study. Subjects will then meet with the treatment team every 2 weeks for rating scale measurements and assessments for side effects. At the end of 8 and 16 weeks, subjects will again undergo RBANS testing. Both subjects and raters will remain blind during the trial
Trial information was received from ClinicalTrials.gov and was last updated in May 2012.
Information provided to ClinicalTrials.gov by Johns Hopkins University.